Document Detail

KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab.
MedLine Citation:
PMID:  23027075     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The prognostic value of KRAS mutation in patients with colorectal cancer liver metastases (CLM) receiving neoadjuvant chemotherapy including bevacizumab before liver resection is unclear.
METHODS: The KRAS and BRAF status of resected CLM was assessed in prospectively studied patients. Mutations were correlated with recurrence-free and overall survival. Only patients with remaining vital tumour cells in the resected specimen and those without disease progression were analysed; those with progressive disease did not undergo resection.
RESULTS: A total of 60 patients were enrolled. Fifteen (25 per cent) had a KRAS mutation, but none of the 60 patients had a BRAF mutation. The radiological response to neoadjuvant chemotherapy including bevacizumab, assessed according to the Response Evaluation Criteria In Solid Tumours, was partial in 52 patients (87 per cent) and the remaining eight had stable disease. The partial response rate was similar in patients with a KRAS mutation and those with the wild-type gene (12 of 15 versus 40 of 45 patients; P = 0·400). KRAS mutation had a negative prognostic effect on recurrence-free survival (hazard ratio (HR) 2·48, 95 per cent confidence interval 1·26 to 4·89; P = 0·009) and overall survival (HR 3·51, 1·30 to 9·45; P = 0·013).
CONCLUSION: This study provided further evidence for the prognostic importance of KRAS status in terms of recurrence-free and overall survival. Neoadjuvant chemotherapy including bevacizumab elicited a response, irrespective of KRAS status, in this selected group of patients with CLM.
S Stremitzer; J Stift; B Gruenberger; D Tamandl; T Aschacher; B Wolf; F Wrba; T Gruenberger
Related Documents :
18453735 - Optimizing local control in anorectal melanoma.
18853035 - Popliteal lymphadenectomy for treating metastatic melanoma: case report.
24746315 - Locally ablative therapies for primary and metastatic liver cancer.
12845635 - Autonomous histopathological regression of primary tumours associated with specific imm...
11380465 - Acute myeloid leukaemia m0: haematological, immunophenotypic and cytogenetic characteri...
23762555 - High-dose interleukin-2 (hd il-2) therapy should be considered for treatment of patient...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The British journal of surgery     Volume:  99     ISSN:  1365-2168     ISO Abbreviation:  Br J Surg     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-02     Completed Date:  2012-12-17     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0372553     Medline TA:  Br J Surg     Country:  England    
Other Details:
Languages:  eng     Pagination:  1575-82     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2012 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
Department of General Surgery, Medical University Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / administration & dosage
Antibodies, Monoclonal, Humanized / administration & dosage
Chemotherapy, Adjuvant
Colorectal Neoplasms / genetics*
Genes, ras / genetics*
Liver Neoplasms / genetics,  secondary*,  therapy
Middle Aged
Mutation / genetics*
Neoplasm Recurrence, Local / genetics
Prospective Studies
Proto-Oncogene Proteins B-raf / genetics*
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V/bevacizumab; EC protein, human; EC Proteins B-raf
Comment In:
Br J Surg. 2012 Nov;99(11):1582-3   [PMID:  23027076 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  External biliary drainage and liver regeneration after major hepatectomy.
Next Document:  Criteria for drain removal following liver resection.